Pfizer (PFE) Current Assets (2009 - 2026)
Pfizer (PFE) posted quarterly Current Assets of $42.8 billion for Q1 2026, down 6.63% year-over-year from $45.9 billion in Q1 2025, and little changed quarter-over-quarter from $42.9 billion in Q4 2025.
Pfizer (PFE) Current Assets (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Current Assets for 18 consecutive years, with $42.8 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 6.63% year-over-year to $42.8 billion; the TTM figure through Mar 2026 stood at $42.8 billion (down 6.63% YoY), while the FY2025 annual figure was $42.9 billion, down 14.81% from the prior year.
- Current Assets held at $42.8 billion in Q1 2026 per PFE's latest filing, from $42.9 billion in the prior quarter.
- Across five years, Current Assets topped out at $73.3 billion in Q3 2023 and bottomed at $5.9 billion in Q3 2023.
- Historically, Current Assets has averaged $44.0 billion across 5 years, with a median of $43.7 billion in 2025.
- On a YoY basis, Current Assets climbed as much as 635.59% in 2024 and fell as far as 48.43% in 2024.
- Pfizer's Current Assets stood at $51.3 billion in 2022, then retreated by 15.46% to $43.3 billion in 2023, then increased by 16.21% to $50.4 billion in 2024, then slipped by 14.81% to $42.9 billion in 2025, then fell by 0.18% to $42.8 billion in 2026.
- Business Quant data shows PFE's Current Assets at $42.8 billion in Q1 2026, $42.9 billion in Q4 2025, and $46.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 41.36 Bn |
| Mar 29, 2026 | 42.82 Bn |
| Dec 31, 2025 | 42.90 Bn |
| Sep 28, 2025 | 46.92 Bn |
| Jun 29, 2025 | 43.70 Bn |
| Mar 30, 2025 | 45.86 Bn |
| Dec 31, 2024 | 50.36 Bn |
| Sep 29, 2024 | 43.22 Bn |
| Jun 30, 2024 | 37.83 Bn |
| Mar 31, 2024 | 42.42 Bn |
| Dec 31, 2023 | 43.33 Bn |
| Sep 30, 2023 | 5.88 Bn |
| Jul 2, 2023 | 73.35 Bn |
| Apr 2, 2023 | 50.08 Bn |
| Dec 31, 2022 | 51.26 Bn |
| Sep 30, 2022 | 5.93 Bn |
| Jul 3, 2022 | 67.47 Bn |
| Apr 3, 2022 | 54.42 Bn |
| Dec 31, 2021 | 59.69 Bn |
| Oct 3, 2021 | 6.89 Bn |